Denali Therapeutics Inc. Common Stock DNLI
$20.14
+2.44%
at last close
Market Cap$3.12 billion
P/E Ratio—
Div Yield—
Volume1.83M
52-Week Range
$12.58$23.77
Key Stats
- Today's Range
- $19.67 – $21.10
- 50-Day Range
- $17.71 – $23.46
- 52-Week Range
- $12.58 – $23.77
- Volume
- 1.83 million shs
- Average Volume
- 1.82 million shs
- Market Cap
- $3.12 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.37
- Price / Sales
- —
Short Interest
- Short Interest
- 1.44%
- Days to Cover
- 5.27
Financials (TTM)
- Revenue
- —
- Net Income
- $-508,017,000
- Net Margin
- —
- Return on Equity
- -54.86%
- Debt-to-Equity
- —
About Denali Therapeutics Inc. Common Stock
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.